Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab

被引：0
|
作者：
Meltzer, S. [1 ]
Berg, J. P. [2 ]
Hamre, H. M. [3 ]
Kersten, C. [4 ]
Hofsli, E. [5 ]
Guren, M. G. [6 ]
Sorbye, H. [7 ]
Flatmark, K. [8 ]
Ree, A. H. [3 ]
机构：
[1] Akershus Univ Sykehus HF, Dept Oncol, Lorenskog, Norway
[2] Univ Oslo, Inst Clin Med, Oslo, Norway
[3] Akershus Univ Hosp HF, Dept Oncol, Lorenskog, Norway
[4] Sorlandet Hosp, Dept Res, Kristiansand, Norway
[5] St Olavs Hosp HF, Dept Oncol, Trondheim, Norway
[6] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[7] Haukeland Univ Sykehus, Dept Oncol, Bergen, Norway
[8] Oslo Univ Hosp, Dept Surg Gastroenterol, Radiumhosp, Oslo, Norway
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
基金：
芬兰科学院;
关键词：
D O I：
10.1016/j.annonc.2023.09.1822
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
632P
引用
收藏
页码：S449 / S449
页数：1
相关论文
共 9 条
  • [1] Early radiologic signal of nivolumab responsiveness after short-course oxaliplatin-based chemotherapy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)
    Meltzer, Sebastian
    Negard, Anne
    Hamre, Hanne Mari
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne Gronlie
    Sorbye, Halfdan
    Flatmark, Kjersti
    Ree, Anne Hansen
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Tumor mutational burden (TMB), BRAF status, and C-reactive protein (CRP) predict response to first-line alternating oxaliplatin-based chemotherapy and nivolumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC)
    Ree, A. H.
    Bousquet, P. A.
    Nilsen, H. L.
    Luders, T.
    Wang, S.
    Visnovska, T.
    Bordin, D. L.
    Hoye, E.
    Hamre, H. M.
    Kersten, C.
    Hofsli, E.
    Guren, M. G.
    Sorbye, H.
    Berg, J. P.
    Flatmark, K.
    Meltzer, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S453 - S453
  • [3] Systemic immune response invoked by short-course oxaliplatin-based chemotherapy (FLOX) for efficacy of sequential immune checkpoint blockade (ICB; nivolumab) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)
    Meltzer, Sebastian
    Flatmark, Kjersti
    Fuglestad, Anniken J.
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Negard, Anne
    Ree, Anne Hansen
    CANCER RESEARCH, 2023, 83 (07)
  • [4] Alternating short-course oxaliplatin-based chemotherapy and nivolumab as first-line treatment of patients with abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC): A randomized phase 2 trial
    Ree, Anne Hansen
    Benth, Jurate Saltyte
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Johansen, Christin
    Negard, Anne
    Esbensen, Ying
    Bjornetro, Tonje
    Juul, Hedvig V.
    Kaveh, Fatemeh
    Inderberg, Else Marit
    Nilsen, Hilde Loge
    Flatmark, Kjersti
    Meltzer, Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study.
    Ree, Anne Hansen
    Hamre, Hanne
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne Gronlie
    Sorbye, Halfdan
    Johansen, Christin
    Negard, Anne
    Flatmark, Kjersti
    Meltzer, Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial
    Ree, Anne Hansen
    Benth, Jurate Saltyte
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Johansen, Christin
    Negard, Anne
    Bjornetro, Tonje
    Nilsen, Hilde L.
    Berg, Jens P.
    Flatmark, Kjersti
    Meltzer, Sebastian
    BRITISH JOURNAL OF CANCER, 2024, 130 (12) : 1921 - 1928
  • [7] Predictive value of tumor mutational burden (TMB) in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC) given first-line oxaliplatinbased chemotherapy and immune checkpoint blockade (ICB)
    Ree, Anne Hansen
    Bousquet, Paula A.
    Nilsen, Hilde L.
    Luders, Torben
    Wang, Shixiong
    Visnovska, Tina
    Bordin, Diana L.
    Hoye, Eirik
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Flatmark, Kjersti
    Meltzer, Sebastian
    CANCER RESEARCH, 2024, 84 (06)
  • [8] Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
    Ree, Anne Hansen
    Hoye, Eirik
    Esbensen, Ying
    Beitnes, Ann-Christin R.
    Negard, Anne
    Bernklev, Linn
    Tetlie, Linn Kruse
    Fretland, Asmund A.
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Nilsen, Hilde L.
    Flatmark, Kjersti
    Meltzer, Sebastian
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [9] CEA response and depth of response (DpR) to predict clinical outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line cetuximab plus oxaliplatin-based chemotherapy: A sub-analysis of the JACCRO CC-05/06 trials.
    Sunakawa, Yu
    Ichikawa, Wataru
    Tsuji, Akihito
    Denda, Tadamichi
    Segawa, Yoshihiko
    Negoro, Yuji
    Shimada, Ken
    Kochi, Mitsugu
    Nakamura, Masato
    Kotaka, Masahito
    Tanioka, Hiroaki
    Takagane, Akinori
    Tani, Satoshi
    Yamaguchi, Tatsuro
    Takeuchi, Masahiro
    Fujii, Masashi
    Nakajima, Toshifusa
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
1